Arrowhead Pharmaceuticals (NASDAQ: ARWR) net income
Arrowhead Pharmaceuticals reported a net loss of $1.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $599.5m. Earnings per share were −$0.01.
Arrowhead Pharmaceuticals's best year of the last 10 was fiscal 2019. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$1.6m | — | −0.2% | −$0.01 |
| 2024 | −$599.5m | — | −16,882.4% | −$5.00 |
| 2023 | −$205.3m | — | −85.3% | −$1.92 |
| 2022 | −$176.1m | — | −72.4% | −$1.67 |
| 2021 | −$140.8m | — | −101.9% | −$1.36 |
| 2020 | −$84.6m | −224.4% | −96.1% | −$0.84 |
| 2019 | $68.0m | — | 40.3% | $0.72 |
| 2018 | −$54.5m | — | −337.3% | −$0.65 |
| 2017 | −$34.4m | — | −109.5% | −$0.47 |
| 2016 | −$81.7m | — | −51,614.6% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arrowhead Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Arrowhead Pharmaceuticals ranks 175th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Arrowhead Pharmaceuticals, −0.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 173rd | Alignment Healthcare | −$0.7m | −0.0% |
| 174th | Certara | −$1.6m | −0.4% |
| 175th | Arrowhead Pharmaceuticals | −$1.6m | −0.2% |
| 176th | InnovAge | −$2.5m | −0.3% |
| 177th | Koru Medical Systems | −$2.6m | −6.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Arrowhead Pharmaceuticals
- How much did Arrowhead Pharmaceuticals earn in fiscal 2025?
- Arrowhead Pharmaceuticals reported a net loss of $1.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $599.5m.
- What are the earnings per share of Arrowhead Pharmaceuticals?
- They were −$0.01 in fiscal 2025, compared with −$5.00 in fiscal 2024.
- What was the most profitable year for Arrowhead Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2019, with $68.0m.
- Where does Arrowhead Pharmaceuticals rank in its sector by net income?
- It ranks 175th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Arrowhead Pharmaceuticals come from?
- From the annual report (Form 10-K) that Arrowhead Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arrowhead Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Arrowhead Pharmaceuticals: the Arrowhead Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.